FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Saved in:
| Title: | FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. |
|---|---|
| Authors: | Subbiah, V.1 (AUTHOR) VSubbiah@mdanderson.org, Iannotti, N.O.2 (AUTHOR), Gutierrez, M.3 (AUTHOR), Smith, D.C.4 (AUTHOR), Féliz, L.5 (AUTHOR), Lihou, C.F.6 (AUTHOR), Tian, C.6 (AUTHOR), Silverman, I.M.6 (AUTHOR), Ji, T.6 (AUTHOR), Saleh, M.7,8 (AUTHOR) |
| Source: | Annals of Oncology. May2022, Vol. 33 Issue 5, p522-533. 12p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 156377828 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Subbiah%2C+V%2E%22">Subbiah, V.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> VSubbiah@mdanderson.org</i><br /><searchLink fieldCode="AR" term="%22Iannotti%2C+N%2EO%2E%22">Iannotti, N.O.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gutierrez%2C+M%2E%22">Gutierrez, M.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Smith%2C+D%2EC%2E%22">Smith, D.C.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Féliz%2C+L%2E%22">Féliz, L.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lihou%2C+C%2EF%2E%22">Lihou, C.F.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tian%2C+C%2E%22">Tian, C.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Silverman%2C+I%2EM%2E%22">Silverman, I.M.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ji%2C+T%2E%22">Ji, T.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saleh%2C+M%2E%22">Saleh, M.</searchLink><relatesTo>7,8</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. May2022, Vol. 33 Issue 5, p522-533. 12p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=156377828 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2022.02.001 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 12 StartPage: 522 Titles: – TitleFull: FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Subbiah, V. – PersonEntity: Name: NameFull: Iannotti, N.O. – PersonEntity: Name: NameFull: Gutierrez, M. – PersonEntity: Name: NameFull: Smith, D.C. – PersonEntity: Name: NameFull: Féliz, L. – PersonEntity: Name: NameFull: Lihou, C.F. – PersonEntity: Name: NameFull: Tian, C. – PersonEntity: Name: NameFull: Silverman, I.M. – PersonEntity: Name: NameFull: Ji, T. – PersonEntity: Name: NameFull: Saleh, M. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: May2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 – Type: issue Value: 5 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
